Drug Profile
PF 06669571
Alternative Names: PF 6669571; PF-06669571Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antiparkinsonians
- Mechanism of Action Dopamine D1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Parkinson's disease
Most Recent Events
- 30 Jan 2018 Discontinued - Phase-I for Cognition disorders (In volunteers) in USA (PO, Capsule) (Pfizer pipeline, March 2018)
- 30 Jan 2018 Discontinued - Phase-I for Cognition disorders (In volunteers) in USA (PO, Suspension) (Pfizer pipeline, March 2018)
- 30 Jan 2018 Discontinued - Phase-I for Parkinson's disease in USA (PO) (Pfizer pipeline, March 2018)